HK1255946A1 - 緩釋奧氮平製劑 - Google Patents

緩釋奧氮平製劑

Info

Publication number
HK1255946A1
HK1255946A1 HK18115019.5A HK18115019A HK1255946A1 HK 1255946 A1 HK1255946 A1 HK 1255946A1 HK 18115019 A HK18115019 A HK 18115019A HK 1255946 A1 HK1255946 A1 HK 1255946A1
Authority
HK
Hong Kong
Prior art keywords
sustained release
olanzapine formulations
release olanzapine
formulations
sustained
Prior art date
Application number
HK18115019.5A
Other languages
English (en)
Inventor
Alan Smith Mark
Claassen-Punt Carine
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of HK1255946A1 publication Critical patent/HK1255946A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
HK18115019.5A 2015-09-21 2018-11-23 緩釋奧氮平製劑 HK1255946A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Publications (1)

Publication Number Publication Date
HK1255946A1 true HK1255946A1 (zh) 2019-09-06

Family

ID=57047342

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115019.5A HK1255946A1 (zh) 2015-09-21 2018-11-23 緩釋奧氮平製劑

Country Status (22)

Country Link
US (3) US20170079985A1 (zh)
EP (2) EP3352735B1 (zh)
JP (2) JP2018527397A (zh)
KR (1) KR20180054627A (zh)
CN (2) CN116942677A (zh)
AR (1) AR106085A1 (zh)
AU (2) AU2016328958B2 (zh)
CA (1) CA2998504C (zh)
CL (1) CL2018000727A1 (zh)
DK (1) DK3352735T3 (zh)
EA (1) EA201890788A1 (zh)
ES (1) ES2960753T3 (zh)
FI (1) FI3352735T3 (zh)
HK (1) HK1255946A1 (zh)
HU (1) HUE063850T2 (zh)
IL (3) IL295161A (zh)
MX (2) MX2018003380A (zh)
NZ (1) NZ740665A (zh)
PL (1) PL3352735T3 (zh)
PT (1) PT3352735T (zh)
TW (1) TWI798161B (zh)
WO (1) WO2017053346A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
CN111836615A (zh) 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
JP4503826B2 (ja) * 1997-09-30 2010-07-14 イーライ リリー アンド カンパニー 2−メチル−チエノ−ベンゾジアゼピン製剤
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ES2315680T3 (es) 2003-06-26 2009-04-01 Psivida Inc. Sistema de distribucion de farmacos de gelificacion in situ.
JP5306599B2 (ja) 2004-01-12 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 長期間送達製剤
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CN101166514A (zh) * 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法
BRPI0613034A8 (pt) * 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
KR20140109509A (ko) 2006-07-11 2014-09-15 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
JP5302952B2 (ja) 2007-04-19 2013-10-02 ドン・ア・ファーム・カンパニー・リミテッド 糖調節ペプチドの制御放出に適した生分解性マイクロスフェア組成物及びその製造方法
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
EP2309982A2 (en) 2008-06-03 2011-04-20 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
EP2323623B1 (en) 2008-08-12 2016-07-27 Novartis AG Pharmaceutical compositions
KR101726715B1 (ko) 2008-10-10 2017-04-13 폴리액티바 피티와이 리미티드 생분해성 폴리머-생물활성 모이어티 공액체
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
WO2010105093A2 (en) 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
ES2699692T3 (es) 2010-01-04 2019-02-12 Mapi Pharma Ltd Sistema de depósito que comprende acetato de glatiramer
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
ES2897976T3 (es) 2010-05-31 2022-03-03 Farm Rovi Lab Sa Composiciones para implantes in situ biodegradables inyectables
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
SG191414A1 (en) 2010-12-29 2013-08-30 Medincell Biodegradable drug delivery compositions
RS60051B1 (sr) 2011-06-10 2020-04-30 Ramscor Inc Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme
ES2632420T3 (es) 2011-10-24 2017-09-13 Braeburn Pharmaceuticals, Inc. Composiciones implantables de administración de fármacos y procedimientos de tratamiento de las mismas
DK2806853T3 (da) 2012-01-23 2020-09-28 Allergan Inc Tidsudløst bionedbrydelige eller bioeroderbare mikrosfærer eller mikropartikler suspenderet i en størknende, depotdannende, injicerbar lægemiddelformulering
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
AU2014283692B2 (en) 2013-06-20 2017-04-27 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
IL295161A (en) 2022-09-01
CA2998504C (en) 2023-06-20
IL258086A (en) 2018-05-31
NZ740665A (en) 2023-04-28
PL3352735T3 (pl) 2024-01-29
CL2018000727A1 (es) 2018-09-28
TWI798161B (zh) 2023-04-11
KR20180054627A (ko) 2018-05-24
AR106085A1 (es) 2017-12-13
AU2016328958A1 (en) 2018-04-05
WO2017053346A1 (en) 2017-03-30
JP2021167331A (ja) 2021-10-21
DK3352735T3 (da) 2023-10-30
AU2016328958B2 (en) 2022-04-21
MX2022007315A (es) 2022-07-13
US20180264001A1 (en) 2018-09-20
MX2018003380A (es) 2018-08-16
HUE063850T2 (hu) 2024-02-28
CA2998504A1 (en) 2017-03-30
TW201726144A (zh) 2017-08-01
AU2022206695A1 (en) 2022-08-11
ES2960753T3 (es) 2024-03-06
EP3352735A1 (en) 2018-08-01
EP4331570A1 (en) 2024-03-06
US20220323458A1 (en) 2022-10-13
PT3352735T (pt) 2023-10-30
US20170079985A1 (en) 2017-03-23
IL275735A (en) 2020-08-31
EP3352735B1 (en) 2023-08-30
CN116942677A (zh) 2023-10-27
FI3352735T3 (fi) 2023-10-20
CN108289834A (zh) 2018-07-17
EA201890788A1 (ru) 2018-09-28
JP2018527397A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
IL265609A (en) New formulations
GB201607918D0 (en) Novel formulations
HK1254343A1 (zh) 藥物製劑
HK1258718A1 (zh) 控釋製劑
HK1258803A1 (zh) 賴諾普利製劑
GB201404139D0 (en) Sustained release buprenorphine solution formulations
ZA201704263B (en) Controlled-release formulations
AU366777S (en) Pessary
GB201419261D0 (en) Formulations
GB201419091D0 (en) Formulations
HK1244714A1 (zh) 阿普斯特緩釋製劑
IL275735A (en) Olanzapine sustained release pharmaceutical preparation
IL258852A (en) Preparations for delayed release of local anesthetics
IL254794A0 (en) Pharmaceutical formulations
HK1252549A1 (zh) 控釋tozadenant製劑
HK1248102A1 (zh) 三脈衝釋放興奮劑製劑
IL247828A0 (en) Progesterone compounds
IL269403A (en) Olanzapine sustained release pharmaceutical preparation
GB201621277D0 (en) Formulations
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations
GB201617866D0 (en) Novel formulations
GB201616509D0 (en) Novel formulations
ZA201606376B (en) Self release nozzle